Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2025 | Dose-escalation and expansion study of 225Ac-J591 in mCRPC

Scott Tagawa • 19 Oct 2025
ESMO 2025
Genitourinary Cancer Prostate Cancer 225Ac-J591

Scott Tagawa, MD, MS, FACP, Weill Cornell Medical Center, New York, NY, comments on results from a Phase I dose-escalation and expansion trial (NCT04506567) evaluating fractionated and multiple-dose regimens of the PSMA-targeted alpha radioligand 225Ac-J591 in patients with metastatic castration-resistant prostate cancer (mCRPC). The fractionated regimen demonstrated manageable safety and preliminary efficacy, with thrombocytopenia identified as the main dose-limiting toxicity. Multiple-dose schedules were less feasible due to hematologic timing, and a multicenter validation study is ongoing. This interview took place at the European Society for Medical Oncology (ESMO) 2025 Congress in Berlin, Germany.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Scott Tagawa

Evaluating adverse events related to 177Lu-PSMA-617 in PSMA-positive mHSPC
0:53
Evaluating adverse events related to 177Lu-PSMA-617 in PSMA-positive mHSPC
Scott Tagawa • 19 Oct 2025
Challenges in identifying patients suited for PSMA-targeted therapies in HSPC
1:24
Challenges in identifying patients suited for PSMA-targeted therapies in HSPC
Scott Tagawa • 19 Oct 2025
PSMAddition: 177Lu-PSMA-617 plus ADT and ARPI in PSMA-positive mHSPC
2:08
PSMAddition: 177Lu-PSMA-617 plus ADT and ARPI in PSMA-positive mHSPC
Scott Tagawa • 19 Oct 2025
Key findings from Phase I/II Study: fractionated Lu-177 PSMA therapy shows safety and promise
0:29
Key findings from Phase I/II Study: fractionated Lu-177 PSMA therapy shows safety and promise
Scott Tagawa • 3 Jun 2024

Related Videos

Enzalutamide outcomes & duration predictors in mHSPC: ARCHES post hoc analyses
3:04
Enzalutamide outcomes & duration predictors in mHSPC: ARCHES post hoc analyses
Andrew Armstrong • 3 Jun 2026
Chemo-IO in neuroendocrine or aggressive variant metastatic prostate cancer
2:24
Chemo-IO in neuroendocrine or aggressive variant metastatic prostate cancer
Andrew Armstrong • 3 Jun 2026
Treatment sequencing after EV plus pembrolizumab in metastatic bladder cancer
2:10
Treatment sequencing after EV plus pembrolizumab in metastatic bladder cancer
Tian Zhang • 1 Jun 2026
Highlights in ADCs for bladder cancer at ASCO 2026
1:29
Highlights in ADCs for bladder cancer at ASCO 2026
Tian Zhang • 1 Jun 2026
The content of VJOncology is intended for healthcare professionals